Cyr61 protein's effect on bone stem cells and age-related bone loss
Role of Cyr61/CCN1 in Mesenchymal Stem Cell Niche and Aging Bone
This work tests whether restoring a protein called Cyr61 in the bone marrow environment can help bone stem cells respond better and support healthier bones in older adults.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rlr VA Medical Center NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11264891 on NIH RePORTER |
What this research studies
Researchers compare the support matrix made by bone marrow cells from young donors versus older donors to see how it affects mesenchymal stem cells (the cells that become bone). They found that older donors' matrix has less Cyr61 and that stem cells on older matrix respond poorly to a bone-growth signal called BMP-2. In the lab, removing Cyr61 from young matrix reduced stem cell responses, while adding Cyr61 back to old stromal cells restored BMP-2 responsiveness, and mouse studies link Cyr61 loss to lower bone density. The team uses cultured human bone marrow cells, gene delivery tools, and mouse models to understand whether fixing Cyr61-related changes could improve bone formation and healing.
Who could benefit from this research
Good fit: Older adults with age-related bone loss, osteoporosis, or delayed fracture healing would be the most relevant group for eventual treatments based on this work.
Not a fit: Young people with normal bone density or patients whose bone problems stem from unrelated causes (for example, some genetic disorders or certain medications) may not benefit from Cyr61-targeted approaches.
Why it matters
Potential benefit: If successful, this could point to new therapies that restore bone stem cell function and improve bone density or fracture healing in older adults.
How similar studies have performed: Preclinical lab and mouse studies indicate Cyr61 affects bone formation and that restoring it can rescue stem cell responses, but human clinical benefits have not yet been demonstrated.
Where this research is happening
Indianapolis, United States
- Rlr VA Medical Center — Indianapolis, United States (Active)
Researchers
- Principal investigator: Marinkovic, Milos — Rlr VA Medical Center
- Study coordinator: Marinkovic, Milos
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.